Giancarlo Pérez-Lazo

Dr. Giancarlo Pérez-Lazo

Division of Infectious Diseases, Hospital Base Guillermo Almenara Irigoyen, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
LVLuis J. del Valle
Luis J. del Valle
RSRoxana Sandoval-Ahumada
Roxana Sandoval-Ahumada
FSFernando Soto-Febres
Fernando Soto-Febres
RCRaúl Castillo-Córdova
Raúl Castillo-Córdova
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
The addition of Biofire® FilmArray® Blood Culture Identification panel 2 (BCID2) to the antimicrobial stewardship program (ASP) could improve outcomes in bloodstream infections (BSI) of patients with febrile neutropenia (FN). A pre- and post-quasi-experimental single-center study was conducted at a reference hospital in Peru. Three groups were considered: patients with BSI before ASP intervention (control group), patients with BSI after ASP intervention (group 1), and patients with BSI after ASP intervention plus BCID2 PCR Panel implementation (group 2). Overall, 93 patients were identified (32 control, 30 group 1, 31 group 2). The median time to effective therapy was significantly shorter in group 2 compared to group 1 and control group, respectively (3.75 vs. 10 h, p = 0.004; 3.75 vs. 19 h, p < 0.001). No significant differences in terms of relapse of bacteremia, in-hospital mortality (all cause), and 30-day-all-cause hospital readmission between the three study periods were found. The appropriateness of empirical antimicrobial use, adding or change, and the following de-escalation or discontinuation was significant when the two intervention periods were compared with the control group (p < 0.001). In addition to the lack of local studies documenting the microbiological profile of FN episodes, adding syndromic panels-based testing could allow for the consolidation of ASP strategies.

1 January 2020 in IDCases
Verified
Journal Article
Open access
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
AMA. Morales-Moreno
A. Morales-Moreno
FSF. Soto-Febres
F. Soto-Febres
HJH. Jove-Químper
H. Jove-Químper
LML. Morales-Castillo
L. Morales-Castillo
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
We report the first case of Myroides phaeus isolated from blood, causing bacteremia in an immunocompromised patient using the automated MicroScan Walk Away 96 system, followed by bacterial identification by amplification-sequencing of the 16S rDNA. The sequences obtained were compared with the reference sequence of the BLAST ® platform - National Library of Medicine, USA, and the isolation was identified as Myroides phaeus strain with 99.67 % identity in Blast report. In the literature we did not find previous reported cases of infections by this bacterium, however its pathogenic role is still controversial; therefore, this isolation alerts us to carry out an exhaustive surveillance of other possible acquisition routes.

1 August 2017 in Revista chilena de infectología
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
JMJulio Maquera-Afaray
Julio Maquera-Afaray
CMChristian R. Mejia
Christian R. Mejia
RCRaúl Castillo
Raúl Castillo
Palabras clave: Histoplasmosis; VIH/SIDA; Perú (fuente: DeCS BIREME)

8 October 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
SASusan Abarca-Salazar
Susan Abarca-Salazar
RLRenata Lovón
Renata Lovón
RRRocío Rojas
Rocío Rojas
JBJosé Ballena-López
José Ballena-López
LILuis Ricardo Illescas
Luis Ricardo Illescas
A descriptive design was carried out studying the correlation between antimicrobial consumption and resistance profiles of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) in a Peruvian hospital, including the surgical, clinical areas and the intensive care unit (ICU) during the time period between 2015 and 2018. There was a significant correlation between using ceftazidime and the increase of carbapenem-resistant Pseudomonas aeruginosa isolations (R = 0.97; p < 0.05) and the resistance to piperacillin/tazobactam in Enterobacter spp. and ciprofloxacin usage (R = 0.97; p < 0.05) in the medical wards. The Pseudomonas aeruginosa resistance to piperacillin/tazobactam and amikacin in the intensive care unit (ICU) had a significant reduction from 2015 to 2018 (67% vs. 28.6%, 65% vs. 34.9%, p < 0.001). These findings give valuable information about the rates and dynamics in the relationship between antibiotic usage and antimicrobial resistance patterns in a Peruvian hospital and reinforce the need for continuous support and assessment of antimicrobial stewardship strategies, including microbiological indicators and antimicrobial consumption patterns.

7 November 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
WCWilmer Gianfranco Silva Caso
Wilmer Gianfranco Silva Caso
LVLuis J. del Valle
Luis J. del Valle
AMAdriana Morales-Moreno
Adriana Morales-Moreno
JBJosé Ballena-López
José Ballena-López
LILuis Ricardo Illescas
Luis Ricardo Illescas
The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.

1 February 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RRRicardo Rabagliati
Ricardo Rabagliati
GSGrace Salazar
Grace Salazar
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
MIMaria Paz Iturrieta
Maria Paz Iturrieta
DPDiana Portillo
Diana Portillo
PGPatricia Garcia
Patricia Garcia
Febrile neutropenia is a life-threatening condition commonly observed in patients with hematologic malignancies. The aim of this article is to provide updated knowledge about bloodstream infections in febrile neutropenia episodes within the Andean region of Latin America. This retrospective study was based in 6 hospitals in Chile, Ecuador, and Peru and included adult patients with acute leukemia or lymphoma and febrile neutropenia between January 2019 and December 2020. Of the 416 febrile neutropenia episodes, 38.7% had a bloodstream infection, 86% of which were caused by gram-negative rods, with Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa being the most frequently identified bacteria. K pneumoniae isolates were more frequently resistant than E coli to cefotaxime (65% vs 39.6%), piperacillin-tazobactam (56.7% vs 27.1%), and imipenem (35% vs 2.1%) and were more frequently multidrug resistant (61.7% vs 12.5%). Among P aeruginosa, 26.7% were resistant to ceftazidime, piperacillin-tazobactam, and imipenem, and 23.3% were multidrug resistant. Overall 30-day mortality was 19.8%, being higher with vs without a bloodstream infection (26.7% vs 15.3%, P = .005). Fever duration was also significantly longer, as well as periods of neutropenia and length of hospital stay for patients with bloodstream infection. Additionally, the 30-day mortality rate was higher for episodes with inappropriate vs appropriate empirical antibiotic therapy (41.2% vs 26.6%, P = .139). Considering the high rates of bacteria-resistant infection and 30-day mortality, it is imperative to establish strategies that reduce the frequency of bloodstream infections, increasing early identification of patients at higher risks of multidrug bacteria resistance, and updating existing empirical antibiotic recommendations.